Analystreport

CRISPR Therapeutics AG (NASDAQ: CRSP) is now covered by analysts at Brookline Capital Acquisition Corp.. They set a "buy" rating and a $143.00 price target on the

CRISPR Therapeutics AG - Common Shares  (CRSP) 
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm Check Earnings Report
US:NASDAQ Investor Relations: nasdaq.com/symbol/crsp/real-time